No Data
No Data
AgeX Therapeutics Reports Q2 Results, Raises Going Concern Doubt
Serina Therapeutics | 10-Q: Q2 2024 Earnings Report
Serina Therapeutics: Factors Raise Substantial Doubt Regarding the Ability of the Co to Continue as a Going Concern. >SER
Serina Therapeutics 2Q Rev $51,000 >SER
Express News | Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of MRNA LNP Formulations at the 4th MRNA-Based Therapeutics Summit
No Data